Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Vindesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 12/20 | 0.85 |
| ▸ | TUBB known ✓ | P07437 | 12/20 | 0.85 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 12/20 | 0.85 |
| ▸ | TUBA1B known ✓ | P68363 | 12/20 | 0.85 |
| ▸ | TUBA4A known ✓ | P68366 | 12/20 | 0.85 |
| ▸ | TUBB4B known ✓ | P68371 | 12/20 | 0.85 |
| ▸ | TUBB3 known ✓ | Q13509 | 12/20 | 0.85 |
| ▸ | TUBB2A known ✓ | Q13885 | 12/20 | 0.85 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 12/20 | 0.85 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 12/20 | 0.85 |
| ▸ | TUBA1A known ✓ | Q71U36 | 12/20 | 0.85 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 12/20 | 0.85 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 12/20 | 0.85 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 12/20 | 0.85 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 12/20 | 0.85 |
| ▸ | MLNR | O43193 | 1/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | GHSR | Q92847 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 5/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vindesine SCHEMBL1650601 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28250735 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28177485 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL29370847 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL29895728 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28186617 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL11481610 | 0.99 | MLNR (0.95) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28212242 | 0.99 | MLNR (0.95) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL16553307 | 0.99 | MLNR (0.95) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL15866615 | 0.98 | MLNR (1.00) | MLNRPTGS2KCNH2GHSRTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22428 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4637751-A2 | FOXM1 INHIBITORS AND THEIR USE IN TREATING CANCERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-10-29 | — | — | EP | claimed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-12325755-B2 | Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-10 | — | — | US | claimed |
| WO-2025087695-A1 | METHOD FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES | ASCEND ADVANCED THERAPIES LTD (GB) | 2025-05-01 | — | — | WO | claimed |
| US-12257251-B2 | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation | INXMED (NANJING) CO., LTD. (CN) | 2025-03-25 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| EP-0912738-A2 | ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS | Novopharm Biotech, Inc. (CA) | 1999-05-06 | — | — | EP | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | claimed |
| WO-1998040088-A1 | COMPOSITIONS FOR TREATING TUMORS CONTAINING SHARK CARTILAGE EXTRACTS AND ANTI-NEOPLASTIC AGENTS | LES LABORATOIRES AETERNA INC. (CA) | 1998-09-17 | — | — | WO | claimed |
| WO-1997044461-A2 | ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS | NOVOPHARM BIOTECH, INC. (CA) | 1997-11-27 | — | — | WO | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| EP-0009996-A1 | Preparation of vindesine monosulfate | ELI LILLY AND COMPANY (US) | 1980-04-16 | — | — | EP | claimed |